AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
+49.95%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.93B
AUM Growth
+$2.93B
(+28%)
Cap. Flow
-$195M
Cap. Flow
% of AUM
-6.63%
Top 10 Holdings %
Top 10 Hldgs %
77.18%
Holding
114
New
14
Increased
16
Reduced
26
Closed
23
Top Buys
| 1 |
argenx
ARGX
|
$44.3M |
| 2 |
Scholar Rock
SRRK
|
$41.4M |
| 3 |
Arrowhead Research
ARWR
|
$31.3M |
| 4 |
Korro Bio
KRRO
|
$20.1M |
| 5 |
Kymera Therapeutics
KYMR
|
$18.5M |
Top Sells
| 1 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$88.2M |
| 2 |
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
|
$69.4M |
| 3 |
Amicus Therapeutics
FOLD
|
$28.9M |
| 4 |
Cytokinetics
CYTK
|
$25.4M |
| 5 |
IMGN
Immunogen Inc
IMGN
|
$24M |
Sector Composition
| 1 | Healthcare | 51.64% |
| 2 | Consumer Discretionary | 47.64% |
| 3 | Technology | 0.45% |
| 4 | Real Estate | 0.14% |
| 5 | Communication Services | 0.09% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CAVA Group
CAVA
$7.83B
| $1.38B | 45.73% | 32,007,990 | – | – |
|
|
2
Scholar Rock
SRRK
$3.14B
| $212M | 7.04% | 11,259,438 +2,199,931 | +24% | +$41.4M |
|
3
Lexicon Pharmaceuticals
LXRX
$400M
| $180M | 5.98% | 117,553,284 | – | – |
|
|
4
Cytokinetics
CYTK
$4.23B
| $101M | 3.37% | 1,214,284 -304,547 | -20% | -$25.4M |
|
5
Apellis Pharmaceuticals
APLS
$3.48B
| $85.1M | 2.83% | 1,421,346 -243,226 | -15% | -$14.6M |
|
|
ONC
6
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $73M | 2.43% | 404,480 +546 | +0.1% | +$98.5K |
|
|
7
Kymera Therapeutics
KYMR
$2.95B
| $64.4M | 2.14% | 2,530,735 +725,389 | +40% | +$18.5M |
|
|
MORF
8
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $61.8M | 2.05% | 2,138,188 | – | – |
|
|
SWTX
9
DELISTED
SpringWorks Therapeutics
SWTX
| $59M | 1.96% | 1,615,348 -201,272 | -11% | -$7.35M |
|
|
SLN
10
Silence Therapeutics
SLN
$227M
| $52.1M | 1.73% | 3,000,000 +500,000 | +20% | +$8.69M |
|
11
Revolution Medicines
RVMD
$7.1B
| $48.6M | 1.62% | 1,695,949 -833,788 | -33% | -$23.9M |
|
|
12
argenx
ARGX
$43.6B
| $44.3M | 1.47% | +116,388 | New | +$44.3M |
|
13
Neumora Therapeutics
NMRA
$280M
| $43.5M | 1.45% | 2,552,702 -250,000 | -9% | -$4.26M |
|
|
14
Arrowhead Research
ARWR
$3.05B
| $31.5M | 1.05% | 1,028,255 +1,022,815 | +18,802% | +$31.3M |
|
|
15
Amicus Therapeutics
FOLD
$2.34B
| $28.8M | 0.96% | 2,026,364 -2,036,203 | -50% | -$28.9M |
|
|
IGMS
16
DELISTED
IGM Biosciences
IGMS
| $25.8M | 0.86% | 3,100,422 +578,178 | +23% | +$4.8M |
|
17
Kura Oncology
KURA
$686M
| $25.4M | 0.85% | 1,768,056 -250,000 | -12% | -$3.6M |
|
|
SLRN
18
DELISTED
ACELYRIN
SLRN
| $22.6M | 0.75% | 3,035,888 +566,609 | +23% | +$4.23M |
|
|
CBIO
19
Crescent Biopharma, Inc. Common Stock
CBIO
$200M
| $20.3M | 0.67% | 8,589,064 | – | – |
|
|
20
Korro Bio
KRRO
$217M
| $20.1M | 0.67% | +418,605 | New | +$20.1M |
|
|
SYRS
21
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
| $19.5M | 0.65% | 2,505,013 +1,029,269 | +70% | +$8.02M |
|
22
Prothena Corp
PRTA
$441M
| $18.2M | 0.61% | +501,360 | New | +$18.2M |
|
23
Denali Therapeutics
DNLI
$2.23B
| $17.2M | 0.57% | 802,899 | – | – |
|
24
Dyne Therapeutics
DYN
$1.92B
| $16.2M | 0.54% | 1,217,960 +402,875 | +49% | +$5.36M |
|
25
Wave Life Sciences
WVE
$1.53B
| $15.2M | 0.5% | 3,007,400 +1,007,400 | +50% | +$5.09M |
|